Apthera, Inc. Files a Phase III Special Protocol Assessment with FDA for NeuVax(TM) in Early-Stage Breast Cancer Patients

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Apthera, Inc. announced today that it has submitted a Phase III clinical protocol and statistical analysis plan for registration of its lead cancer therapeutic, NeuVax™ to the FDA for review under a Special Protocol Assessment (“SPA”). The international Phase III randomized, double-blind, placebo-controlled study will compare Standard of Care treatment (SoC) versus SoC plus NeuVax for the prevention of recurrence in early-stage, node-positive breast cancer patients.